Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
134 stopped studies mapped to Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma and descendants · 83% state a reason
Over the 134 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05156229 | A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).(Part B) | Phase 1 | terminated | Dec 14, 2021 | Codiak BioSciences | PK/PD from two patients plus the healthy volunteer data confirmed the RP2D and manageable safety… | Safety / toxicity |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With…(SOLAR) | Phase 2 | terminated | Oct 19, 2018 | miRagen Therapeutics, Inc. | The study was terminated early for business reasons, and not due to concerns regarding safety or… | Safety / toxicity |
| NCT02323659 | Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous… | Phase 4 | terminated | Dec 23, 2014 | Polish Lymphoma Research Group | Slow recruitment | Enrollment / accrual |
| NCT00476554 | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous… | Phase 2 | terminated | May 22, 2007 | Cyclacel Pharmaceuticals, Inc. | slow accrual and financial resource limitation | Enrollment / accrual |
| NCT01420679 | Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral… | Phase 3 | terminated | Aug 22, 2011 | Spectrum Pharmaceuticals, Inc | not stated | Not stated |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+… | Phase 1 / Phase 2 | terminated | Mar 5, 2013 | Northwestern University | Lack of funding | Funding |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell… | Phase 2 | terminated | Jun 25, 2007 | Novartis Pharmaceuticals | Recruitment was stopped on 15 June 2009 (early termination date) due to low prevalence of study… | Enrollment / accrual |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | Phase 1 | terminated | Jul 19, 2012 | Aptevo Therapeutics | Business decision | Sponsor / business decision |
| NCT02301494 | Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma(CTCL) | N/A | withdrawn | Nov 26, 2014 | Rochester General Hospital | No participants were enrolled in the study. | Enrollment / accrual |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | Phase 2 | terminated | Jan 19, 2015 | Rochester General Hospital | Low enrollment | Enrollment / accrual |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With… | Phase 1 | terminated | Sep 5, 2012 | Fred Hutchinson Cancer Center | Terminated due to low accrual. | Enrollment / accrual |
| NCT03719898 | Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma | Phase 2 | withdrawn | Oct 25, 2018 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT03837457 | PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who…(PRISM) | Phase 2 | terminated | Feb 12, 2019 | miRagen Therapeutics, Inc. | Study no longer needed because eligible subjects may receive treatment with cobomarsen in a… | Other (stated, no rule matched) |
| NCT04230330 | Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma | Phase 1 | withdrawn | Jan 18, 2020 | National Cancer Centre, Singapore | PI has left the institution. | Other (stated, no rule matched) |
| NCT03553914 | PLM60 for Peripheral T Cell Lymphoma (PTCL) | Phase 1 / Phase 2 | withdrawn | Jun 12, 2018 | Conjupro Biotherapeutics, Inc. | IND Inactive Status | Other (stated, no rule matched) |
| NCT00632827 | Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using… | Phase 2 | terminated | Mar 11, 2008 | University of California, San Francisco | Manufacturing shortage of both Diftitox and Doxil | Drug supply |
| NCT03617224 | Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary… | Phase 1 | withdrawn | Aug 6, 2018 | University of Texas Southwestern Medical Center | Unable to enroll patients that met enrollment criteria. | Enrollment / accrual |
| NCT03075553 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | Phase 2 | terminated | Mar 9, 2017 | Mayo Clinic | due to poor response | Other (stated, no rule matched) |
| NCT01609816 | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for… | Phase 1 | terminated | Jun 1, 2012 | Barbara Ann Karmanos Cancer Institute | Low accrual. No Analyses were performed | Enrollment / accrual |
| NCT01742793 | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid)…(RID) | Phase 1 | terminated | Dec 5, 2012 | Yale University | The study was terminated due to withdrawal of institutional support, Phase II never began. | Other (stated, no rule matched) |
| NCT02465528 | Ceritinib Rare Indications Study in ALK+ Tumors | Phase 2 | terminated | Jun 8, 2015 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01445340 | Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma | Phase 1 | terminated | Oct 3, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02087878 | A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel…(HSTCL) | — | withdrawn | Mar 14, 2014 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02729961 | Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic… | Phase 1 / Phase 2 | withdrawn | Apr 6, 2016 | University of Washington | Administrative closure | Other (stated, no rule matched) |
| NCT01738594 | Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell… | Phase 1 | terminated | Nov 30, 2012 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating… | N/A | terminated | Aug 3, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03373305 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory… | Phase 1 | withdrawn | Dec 14, 2017 | City of Hope Medical Center | contract not executed | Other (stated, no rule matched) |
| NCT01948180 | Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma(CITADEL) | Phase 2 | terminated | Sep 23, 2013 | Cell Medica Ltd | Insufficient enrollment rate | Enrollment / accrual |
| NCT02061449 | Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma | Phase 1 | terminated | Feb 12, 2014 | NYU Langone Health | Low Accrual | Enrollment / accrual |
| NCT02556463 | A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With… | Phase 1 | terminated | Sep 22, 2015 | MedImmune LLC | Company strategy | Sponsor / business decision |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | Phase 2 | terminated | Aug 13, 2009 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT01663571 | STAT3 in T Cells: At The Crossroads of Inflammation and Cancer | — | terminated | Aug 13, 2012 | NYU Langone Health | Study is permanently closed to enrollment .Collection of private identifiable information is… | Enrollment / accrual |
| NCT02359162 | Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat… | Phase 3 | terminated | Feb 9, 2015 | Sun Yat-sen University | The study is out of date | Other (stated, no rule matched) |
| NCT02533323 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | Phase 2 | terminated | Aug 26, 2015 | Sun Yat-sen University | not stated | Not stated |
| NCT03235869 | Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma | Early Phase 1 | withdrawn | Aug 1, 2017 | University of Michigan Rogel Cancer Center | The company pulled durvalumab from heme malignancies | Sponsor / business decision |
| NCT00354107 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent… | Phase 1 / Phase 2 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03205891 | Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin… | Phase 1 | withdrawn | Jul 2, 2017 | M.D. Anderson Cancer Center | Change in treatment priorities for these disease types as well as staffing concerns. | Other (stated, no rule matched) |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | Phase 1 / Phase 2 | terminated | Aug 24, 2010 | Stanford University | Business decision by funding source | Funding |
| NCT01419795 | Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed… | Phase 2 | terminated | Aug 18, 2011 | Fred Hutchinson Cancer Center | Low accrual | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | — | terminated | Sep 28, 2009 | Stanford University | Competing studies | Other (stated, no rule matched) |
| NCT01625455 | Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary… | Phase 4 | terminated | Jun 21, 2012 | Vanderbilt University Medical Center | Difficulty recruiting. | Enrollment / accrual |
| NCT01841021 | Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma… | N/A | terminated | Apr 26, 2013 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual, loss of sponsor support | Enrollment / accrual |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | Phase 2 | terminated | Jul 10, 2012 | Adam Lerner | Poor enrollment | Enrollment / accrual |
| NCT02487316 | A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib | Phase 4 | withdrawn | Jul 1, 2015 | Jun Zhu | not stated | Not stated |
| NCT00226993 | Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With… | Phase 1 / Phase 2 | withdrawn | Sep 27, 2005 | Stanford University | not stated | Not stated |
| NCT02757248 | Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL | Phase 1 | withdrawn | May 2, 2016 | Anne Beaven, MD | Boehringer Ingelheim is discontinuing their volasertib development program | Other (stated, no rule matched) |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T…(Gifox-B) | Phase 2 | terminated | Jun 21, 2016 | National Cancer Centre, Singapore | Slow recruitment | Enrollment / accrual |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | Phase 1 / Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | Administratively Complete | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 2, 2022source: clinicaltrials